February 12, 2008 - Altor BioScience Corporation (Altor) announced it has entered into an agreement with Genentech, Inc. for exclusive, worldwide rights to develop and commercialize a class of antibody-based Tissue Factor antagonists. Altor plans on initiating a multi-center, 
Phase II clinical study later this year, using the lead therapeutic antibody known as ALT-836 for the treatment of Acute Respiratory Distress Syndrome (ARDS) and Acute Lung Injury (ALI)... Altor BioScience's Press Release -
